Bristol Myers Squibb raised its full-year revenue outlook after reporting higher third-quarter revenue.
The company's updated guidance reflects stronger-than-expected performance during the quarter, driven by continued demand for its key pharmaceutical products.
Analysts noted that the revised outlook signals improving momentum for Bristol Myers Squibb, particularly as it navigates patent expirations and competition in the oncology and immunology markets.
The Wall Street Journal reported that the upward revision highlights the company's successful cost-cutting measures and portfolio optimization efforts, reinforcing confidence among investors.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing